Mirabegron

 Astellas Pharma Inc is a Japanese pharmaceutical company, formed on 1 April 2005

 Discovery → Mirabegron was developed by Astellas Pharma, a Japanese pharmaceutical company, as a selective β3-adrenoceptor agonist.

2003–2009 → Early clinical trials showed that stimulation of β3 receptors in the bladder detrusor muscle could improve bladder storage without the anticholinergic side effects.

 2011 (Japan) → First approval for treatment of overactive bladder (OAB).

2012 (Europe) → Approved by the European Medicines Agency (EMA) under the trade name Betmiga.

2012 (USA) → Approved by the FDA under the trade name Myrbetriq.

Mechanism Of Actions 

Beta 3 Agonist 

Relaxes Bladder

Stores Urine 

Uses: Treatment Of Overactive Bladder

Snapshot